title: PKR is activated in MDS patients and its subcellular localization depends on disease severity.
authors.forename: M Y
authors.initials: MY
authors.lastname: Follo
authors.forename: C
authors.initials: C
authors.lastname: Finelli
authors.forename: S
authors.initials: S
authors.lastname: Mongiorgi
authors.forename: C
authors.initials: C
authors.lastname: Clissa
authors.forename: C
authors.initials: C
authors.lastname: Bosi
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: W L
authors.initials: WL
authors.lastname: Blalock
authors.forename: L
authors.initials: L
authors.lastname: Cocco
authors.forename: A M
authors.initials: AM
authors.lastname: Martelli
mesh_terms: D002467:Cell Nucleus / Q000201:enzymology; D003593:Cytoplasm / Q000201:enzymology; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000453:epidemiology / Q000378:metabolism*; D012307:Risk Factors; D012720:Severity of Illness Index; D019892:eIF-2 Kinase / Q000378:metabolism*
chemical_list: D019892:eIF-2 Kinase